Zobrazeno 1 - 10
of 266
pro vyhledávání: '"Haralabos P, Kalofonos"'
Autor:
Chaido Sirinian, Anastasios D. Papanastasiou, Ozge Karayel, Soren E. Degn, Stavros Peroukidis, Dimitrios Chaniotis, Afrodite Nonni, Maria Repanti, Mark Kriegsmann, Thomas Makatsoris, Angelos Koutras, Matthias Mann, Haralabos P. Kalofonos
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 33, Iss , Pp 100836- (2022)
Breast cancer is a highly heterogeneous disease both at the histological and molecular levels. We have previously shown that RANK-c is a regulator of NF-κB signaling and exerts a suppressive effect on aggressive properties of ER negative breast canc
Externí odkaz:
https://doaj.org/article/5f86f086b12f4ca3a84b02b36b1aed58
Autor:
Foteinos-Ioannis D. Dimitrakopoulos, Anna G. Antonacopoulou, Anastasia E. Kottorou, Melpomeni Kalofonou, Nikolaos Panagopoulos, Dimitrios Dougenis, Thomas Makatsoris, Vasiliki Tzelepi, Angelos Koutras, Haralabos P. Kalofonos
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundImmune system-related receptors CD40 (tumor necrosis factor receptor superfamily member 5), BAFFR (tumor necrosis factor receptor superfamily member 13C), and LTβR (tumor necrosis factor receptor superfamily member 3) play a pivotal role i
Externí odkaz:
https://doaj.org/article/c8a31c79958046baaea54e62931e3ee1
Autor:
Foteinos-Ioannis D. Dimitrakopoulos, Anna G. Antonacopoulou, Anastasia E. Kottorou, Nikolaos Panagopoulos, Fotini Kalofonou, Fotios Sampsonas, Chrisoula Scopa, Melpomeni Kalofonou, Angelos Koutras, Thomas Makatsoris, Dimitrios Dougenis, Helen Papadaki, Malcolm Brock, Haralabos P. Kalofonos
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Abstract A growing number of studies has shed light on the role of the NF-κΒ in non-small-cell lung cancer (NSCLC). To address the significance of major effectors of the NF-κΒ alternative pathway, we investigated the relationship between NF-κΒ2
Externí odkaz:
https://doaj.org/article/90d7b523d73d42dd8591096c779df15c
Autor:
Anna Antonacopoulou, Anastasia E. Kottorou, Foteinos-Ioannis Dimitrakopoulos, Stella Marousi, Foteini Kalofonou, Angelos Koutras, Thomas Makatsoris, Vassiliki Tzelepi, Haralabos P. Kalofonos
Publikováno v:
Translational Oncology, Vol 14, Iss 1, Pp 100912- (2021)
The Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) family of transcription factors plays an important role in immune responses and cancer development and progression. We have focused on NF-κB2 and RELB of the alternative pat
Externí odkaz:
https://doaj.org/article/11732b97e40845a4ad6406542d815274
Autor:
Panagiota M. Kalligosfyri, Sofia Nikou, Sofia Karteri, Haralabos P. Kalofonos, Vasiliki Bravou, Despina P. Kalogianni
Publikováno v:
Biosensors, Vol 12, Iss 2, p 97 (2022)
In the era of personalized medicine, molecular profiling of patient tumors has become the standard practice, especially for patients with advanced disease. Activating point mutations of the KRAS proto-oncogene are clinically relevant for many types o
Externí odkaz:
https://doaj.org/article/8f71216e056941a395e40285defa8988
Autor:
Foteinos-Ioannis D. Dimitrakopoulos, Eleni Kourea, George Nasioulas, Eirini Papadopoulou, Achilles Nikolakopoulos, Despoina Spyropoulou, Anastasia Kottorou, Andreas Karatzas, Haralabos P. Kalofonos, Angelos Koutras
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Immunotherapy may result in long-lasting exceptional clinical responses, the molecular background of which is inadequately understood. Here, we present the case of a 63-year-old patient with a past medical history of renal cancer who relapsed many ye
Externí odkaz:
https://doaj.org/article/1b8c4ddadd5b4d9d9bb369423fecc871
Autor:
Haralabos P. Kalofonos, Melpomeni Kalofonou, Anastasia E. Kottorou, Foteinos-Ioannis D. Dimitrakopoulos
Supplementary Table S2. Published studies on genetic variations of NF-κB family members and their clinical significance in NSCLC.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b1c82c87ae3fcad35c49c464821cd3c
https://doi.org/10.1158/0008-5472.22425417.v1
https://doi.org/10.1158/0008-5472.22425417.v1
Autor:
Haralabos P. Kalofonos, Melpomeni Kalofonou, Anastasia E. Kottorou, Foteinos-Ioannis D. Dimitrakopoulos
Supplementary Figure S1. Hallmarks of lung cancer influenced by NF-κB activity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6210ba999de79b46629e6b6e33336338
https://doi.org/10.1158/0008-5472.22425423
https://doi.org/10.1158/0008-5472.22425423
Autor:
Haralabos P. Kalofonos, Melpomeni Kalofonou, Anastasia E. Kottorou, Foteinos-Ioannis D. Dimitrakopoulos
Thirty-four years since its discovery, NF-κB remains a transcription factor with great potential for cancer therapy. However, NF-κB–targeted therapies have yet to find a way to be clinically translatable. Here, we focus exclusively on the role of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::862f11defaddefc1eeefd9caa436adb8
https://doi.org/10.1158/0008-5472.c.6512031.v1
https://doi.org/10.1158/0008-5472.c.6512031.v1
Autor:
Vasso Episkopou, Haralabos P. Kalofonos, Vasiliki Bravou, Alexios A. Panoutsopoulos, Shinya Tanaka, Anna G. Antonacopoulou, Vikas Sharma
Supplementary Methods, Table 1, Figures 1-2 from Enhancement of TGF-β Signaling Responses by the E3 Ubiquitin Ligase Arkadia Provides Tumor Suppression in Colorectal Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::deb691c8b61be2fbd95993dcf181ae5b
https://doi.org/10.1158/0008-5472.22388789.v1
https://doi.org/10.1158/0008-5472.22388789.v1